Levodopa-Induced Dyskinesias in Patients with Parkinson’s Disease in the Uzbek Population
Objective: To investigate the clinical features and prevalence of levodopa-induced dyskinesias in patients with Parkinson’s disease in the Uzbek population. Background: Levodopa-induced dyskinesias (LID) are…Oral D1-like/D2-like Receptor Agonist, Lu AF28996, Provides Robust Antiparkinsonian Efficacy with Reduced Dyskinesia in the MPTP-Macaque Model
Objective: Evaluate the therapeutic potential of Lu AF28996 in the MPTP-macaque model of PD. Background: Chronic levodopa treatment is associated with the development of motor…Lu AF28996, a Novel Oral D1-like/D2-like Receptor Agonist, May Improve Motor Complications in People with Parkinson’s Disease: Results from an 18-week open-label, Phase 1b Trial
Objective: Evaluate safety, tolerability, and clinical effects of Lu AF28996 in patients with inadequately controlled advanced Parkinson’s disease (PD) experiencing motor fluctuations, with or without…Caffeine and Tobacco Exposure and the Presence of Levodopa-Induced Dyskinesia (LID) in the STAT-PD Trial
Objective: Using data from the STAT-PD trial, ClinicalTrials NCT # 4064294, we examined whether lifetime caffeine and nicotine exposure are associated with the presence and…Effects of Chronic IEM-1460 Treatment on Perineuronal Net–Parvalbumin Interneuron Association in L-DOPA-Induced Dyskinesia
Objective: To determine whether chronic IEM-1460 administration alters dyskinesia and perineuronal net (PNN)–parvalbumin interneuron (PV-IN) association in a 6-OHDA rat model of L-DOPA-induced dyskinesia (LID).…Phenytoin Intoxication Masquerading as Generalized Chorea: A Case of Iatrogenic Double-Prescribing
Objective: To report a rare case of phenytoin-induced generalized chorea resulting from inadvertent medication duplication across multiple healthcare facilities, highlighting a preventable cause of acute…Effectiveness of Switching from Levodopa-Carbidopa Intestinal Gel to Levodopa-Carbidopa-Entacapone Intestinal Gel in Patients with Refractory Biphasic and Peak-of-Dose Dyskinesia
Objective: To evaluate the clinical benefit on motor complications of transitioning from levodopa-carbidopa intestinal gel (LCIG) to levodopa-carbidopa-entacapone intestinal gel (LECIG) in a cohort of…Subthalamic Beta Sub-band Composition and Gamma Dynamics Across Medication and Stimulation States in Parkinson’s Disease
Objective: To examine how levodopa pharmacodynamics and therapeutic deep brain stimulation (DBS) shape beta sub-band composition and gamma oscillations in the subthalamic nucleus (STN), and…Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson’s Disease: Extension Study of Long-term outcomes of Single Centre experience
Objective: evaluate the long-term outcomes of levodopa-carbidopa intestinal gel (LCIG) infusion in patients with advanced PD with motor fluctuation in one centre Background: Levodopa-carbidopa intestinal…Efficacy and Safety of Mesdopetam (IRL790) for Levodopa Induced Dyskinesia in Parkinson’s Disease: A Meta analysis of Randomized Controlled Trials
Objective: To evaluate the efficacy and safety of mesdopetam compared with placebo for levodopa‑induced dyskinesia (LID) in Parkinson’s disease (PD). Background: Mesdopetam (IRL790) is a…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 49
- Next Page »